Inactive Instrument

GINO BIOW Share Price Nasdaq

Equities

DNA

US37611X1000

Biotechnology & Medical Research

Sales 2024 * 199M 15.92B Sales 2025 * 265M 21.14B Capitalization 1.68B 134B
Net income 2024 * -569M -45.44B Net income 2025 * -479M -38.26B EV / Sales 2024 * 5.33 x
Net cash position 2024 * 613M 48.97B Net cash position 2025 * 557M 44.47B EV / Sales 2025 * 4.23 x
P/E ratio 2024 *
-2.43 x
P/E ratio 2025 *
-3 x
Employees 1,218
Yield 2024 *
-
Yield 2025 *
-
Free-Float 67.67%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder - 31/12/07
Founder - 31/12/07
Founder 43 31/12/07
Members of the board TitleAgeSince
Director/Board Member 56 15/09/21
Director/Board Member 74 31/12/20
Chairman 65 15/09/21
More insiders
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
More about the company